Skip to Main Content




Source: Chan CYJ, Frie-Jones M. Sickle cell disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; 2017. Accessed on May 17, 2017.




  • Group of hereditary disorders characterized by presence of sickle cell hemoglobin (HbS) in red blood cells (RBCs).

    • Homozygous HbS (HbSS) is sickle cell anemia (SCA).

    • Heterozygous inheritance of HbS compounded with another mutation results in:

      • Sickle cell hemoglobin C (HbSC)

      • Sickle cell β-thalassemia.

      • Other rare phenotypes.

  • Sickle cell trait (SCT)

    • Heterozygous inheritance of 1 normal cell and 1 sickle cell hemoglobin gene (HbAS).




  • Normal Hg (hemoglobin A [HbA]) composed of 2 α chains and 2 β chains.

  • Biochemical defect in SCD involves amino acid substitution in the β-polypeptide chain.

    • Leads to sickling and related sequelae.




  • Clinical manifestations of SCD attributable to:

    • Impaired circulation.

    • RBC destruction.

      • Typical sickle cell survives for 10–20 days.

      • Normal RBC lifespan 100–120 days.

    • Stasis of blood flow.

  • Above problems directly related to RBC polymerization.

    • Allows deoxygenated hemoglobin to exist as semisolid gel.

      • Protrudes into cell membrane, distorting RBCs into sickle shapes.

        • Increases blood viscosity.

        • Encourages sludging in the capillaries and small vessels, which leads to local tissue hypoxia that accentuates pathologic process.

      • Repeated cycles of sickling, upon deoxygenation, and unsickling, upon oxygenation, damage RBC membrane and cause irreversible sickling.

      • Rigid, sickled RBCs easily trapped, shortening their circulatory survival and resulting in chronic hemolysis.

    • Membrane damage.

      • Promotes cell recognition by macrophages.

  • Other factors responsible for clinical manifestations of SCD

    • Obstruction of blood flow to spleen, resulting in functional asplenia.

      • Increased susceptibility to infection by encapsulation organisms.

    • Deficient opsonization.

    • Coagulation abnormalities.




  • Most common in people with African heritage.

  • About 2 million Americans have SCT with a prevalence rate of 1 in 13 African Americans and 1 in 100 Hispanics.

  • Incidence of sickle cell gene in population correlates with historical incidence of malaria.

    • SCD gene mutation offers partial protection against malaria.




  • SCD usually identified by routine neonatal screening programs.

    • Infants with positive screening should be tested before 2 months of age to confirm diagnosis.




  • Inherited disorder.




  • SCD involves multiple organ systems. Clinical manifestations depend on genotype (Table 1).

Table Graphic Jump Location
TABLE 1.Clinical Features of Sickle Cell Trait and Common Types of Sickle Cell Disease

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.